Showing results (21-30 of 56) with videos related to
Sort By:
Pageof 6
Leukemia & Lymphoma|June 6, 2014
Src family kinases and their role in hematological malignanciesMatthew Ku, Meaghan Wall, Ruth N MacKinnon, et al.Cancer|March 20, 2014
Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage studyZoe K McQuilten, Erica M Wood, Mark N Polizzotto, et al.The Journal of Clinical Investigation|June 25, 2014
The Rothmund-Thomson syndrome helicase RECQL4 is essential for hematopoiesisMonique F Smeets, Elisabetta DeLuca, Meaghan Wall, et al.Cancer Genetics|December 28, 2011
Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromesKathryn A Kolquist, Roger A Schultz, Aubry Furrow, et al.Cell Reports|February 3, 2016
The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell LymphomaDavid M Wong, Lingli Li, Sabine Jurado, et al.Cellular and Molecular Life Sciences : CMLS|August 14, 2023
Characterization of K562 cells: uncovering novel chromosomes, assessing transferrin receptor expression, and probing pharmacological therapiesTom C Karagiannis, Meaghan Wall, Katherine Ververis, et al.The EMBO Journal|July 30, 2004
MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiationGretchen Poortinga, Katherine M Hannan, Hayley Snelling, et al.Blood|June 16, 2018
Srsf2 initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cellsMonique F Smeets, Shuh Ying Tan, Jane Jialu Xu, et al.Blood|May 6, 2017
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclaxMary Ann Anderson, Constantine Tam, Thomas E Lew, et al.Blood Advances|January 15, 2020
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 monthsThomas E Lew, Mary Ann Anderson, Victor S Lin, et al.Pageof 6